• MK-4305 (Suvorexant) CAS 1030377-33-3

    We have larger quantity for suvorexant and can be sent out immediately once we get your payment Suvorexant, also known as MK-4305, is a dual orexin receptor antagonist in development by Merck & Co. for the treatment of insomnia. Suvorexant is not currently approved for commercial use, but Suvorexant has completed three Phase III trials. Results look promising. The recent FDA review showed that the drug is associated with increased somnolence the next day and users of higher doses had an increased rate of suicidal ideation. Suvorexant works by turning off wakefulness rather than by inducing sleep.

    Email Details
Get the latest price? We'll respond as soon as possible(within 12 hours)

Privacy policy